Hanseatic Management Services’s Ligand Pharmaceuticals LGND Stock Holding History

Hanseatic Management Services’s Portfolio LGND Stock Details LGND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-12,534	Closed	-$933K	–	328
2016 Q2	$933K	Buy	12,534 +96	+0.8%	+$7.12K	0.35%	93
2016 Q1	$831K	Buy	12,438 +32	+0.3%	+$1.95K	0.3%	102
2015 Q4	$839K	Buy	+12,406	New	+$766K	0.29%	113
2015 Q3	–	Sell	-3,547	Closed	-$223K	–	419
2015 Q2	$223K	Buy	+3,547	New	+$194K	0.1%	165

Other funds holding LGND

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DMK

David M. Knott $275M AUM 59.23% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ORI

Oak Ridge Investments Chicago, Illinois $1.51B AUM 37.25% 1-Year Est. Return

CCMLC

Cardinal Capital Management LLC (Connecticut) Greenwich, Connecticut $365M AUM 18.32% 1-Year Est. Return

Hanseatic Management Services's LGND Position: Q3 2016 in Review

Hanseatic Management Services sold out of Ligand Pharmaceuticals (LGND) in Q3 2016, closing a stake of 12,534 shares — an estimated $933K sold.

Hanseatic Management Services first reported a position in LGND in Q2 2015 and held it in 4 quarters. The position peaked at $933K in Q2 2016. 259 funds tracked by Wall St. Rank hold LGND as of Q3 2016.

Hanseatic Management Services reported no remaining Ligand Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Hanseatic Management Services sold 12,534 Ligand Pharmaceuticals shares in Q3 2016, an estimated $933K.
Hanseatic Management Services first reported a position in Ligand Pharmaceuticals in Q2 2015 and held it in 4 quarters.
Hanseatic Management Services's Ligand Pharmaceuticals position peaked at $933K in Q2 2016.
259 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2016.

Based on Hanseatic Management Services's 13F filing for Q3 2016, filed 2 Nov 2016.